Fate Therapeutics (FATE) Competitors $1.08 -0.07 (-5.65%) Closing price 03:59 PM EasternExtended Trading$1.13 +0.04 (+4.15%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. MBX, ATYR, SLDB, AUTL, PRME, ERAS, ETON, CGEM, TNXP, and ITOSShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include MBX Biosciences (MBX), aTyr Pharma (ATYR), Solid Biosciences (SLDB), Autolus Therapeutics (AUTL), Prime Medicine (PRME), Erasca (ERAS), Eton Pharmaceuticals (ETON), Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors MBX Biosciences aTyr Pharma Solid Biosciences Autolus Therapeutics Prime Medicine Erasca Eton Pharmaceuticals Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics Fate Therapeutics (NASDAQ:FATE) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment. Is FATE or MBX more profitable? MBX Biosciences has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,025.05%. MBX Biosciences' return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,025.05% -50.95% -36.76% MBX Biosciences N/A N/A N/A Which has higher valuation & earnings, FATE or MBX? MBX Biosciences has lower revenue, but higher earnings than Fate Therapeutics. MBX Biosciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$8.47M14.77-$186.26M-$1.45-0.75MBX BiosciencesN/AN/AN/A-$4.54-3.07 Do analysts prefer FATE or MBX? Fate Therapeutics currently has a consensus price target of $3.30, suggesting a potential upside of 204.15%. MBX Biosciences has a consensus price target of $37.63, suggesting a potential upside of 169.91%. Given Fate Therapeutics' higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in FATE or MBX? 97.5% of Fate Therapeutics shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by insiders. Comparatively, 52.2% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to FATE or MBX? In the previous week, Fate Therapeutics had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Fate Therapeutics and 3 mentions for MBX Biosciences. Fate Therapeutics' average media sentiment score of 0.54 beat MBX Biosciences' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryFate Therapeutics beats MBX Biosciences on 7 of the 13 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.13M$3.06B$5.75B$9.73BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-0.7520.9930.2525.89Price / Sales14.77387.70474.39123.10Price / CashN/A43.2325.7828.79Price / Book0.399.639.426.00Net Income-$186.26M-$54.08M$3.27B$265.29M7 Day Performance-9.58%2.70%2.08%2.59%1 Month Performance-12.50%4.14%3.63%0.98%1 Year Performance-71.74%9.46%30.13%18.75% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.9875 of 5 stars$1.09-5.7%$3.30+204.1%-70.1%$125.13M$8.47M-0.75550Analyst RevisionMBXMBX Biosciences1.9307 of 5 stars$14.57-1.0%$37.63+158.2%N/A$489.47MN/A-3.2136ATYRaTyr Pharma2.1146 of 5 stars$4.91+0.2%$21.25+332.8%+183.1%$480.14M$230K0.0053News CoverageAnalyst ForecastSLDBSolid Biosciences3.4099 of 5 stars$6.03-1.3%$15.00+148.8%-38.0%$475.78M$8.09M0.00100AUTLAutolus Therapeutics2.5636 of 5 stars$1.88+5.6%$9.12+385.1%-56.1%$473.73M$10.12M-2.24330PRMEPrime Medicine2.6942 of 5 stars$3.50-2.0%$8.92+154.8%-19.7%$471.01M$4.96M-1.71234ERASErasca1.9226 of 5 stars$1.53-6.7%$4.29+180.1%-41.8%$465.22MN/A0.00120News CoverageAnalyst DowngradeETONEton Pharmaceuticals2.1469 of 5 stars$16.37-3.9%$29.67+81.2%+281.1%$456.97M$39.01M0.0020Positive NewsCGEMCullinan Therapeutics1.9128 of 5 stars$7.95+3.8%$28.60+259.7%-54.6%$452.51MN/A0.0030News CoverageAnalyst RevisionTNXPTonix Pharmaceuticals2.9848 of 5 stars$40.07-22.0%$70.00+74.7%+11.7%$450.13M$10.09M-1.0250High Trading VolumeITOSiTeos Therapeutics2.6874 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M0.0090 Related Companies and Tools Related Companies MBX Biosciences Alternatives aTyr Pharma Alternatives Solid Biosciences Alternatives Autolus Therapeutics Alternatives Prime Medicine Alternatives Erasca Alternatives Eton Pharmaceuticals Alternatives Cullinan Therapeutics Alternatives Tonix Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access